

Lumos expands distribution partnership in Australia, New Zealand for rapid POC test

05 July 2024 | News

FebriDx is a rapid point-of-care (POC) test to differentiate a viral from bacterial acute respiratory infection



FebriDx, Lumos' rapid point-of-care test, is now available to healthcare practitioners in Australia and New Zealand, following the signing of a distribution agreement with Regional Health Care Group (RHCG), a Henry Schein company in Australia and New Zealand.

FebriDx is a rapid POC test to differentiate a viral from bacterial acute respiratory infection. FebriDx delivers results after 10 minutes from fingerstick blood and can be used to help rapidly and accurately manage infectious patients in Primary Care, Urgent Care, Emergency Dept, Paediatric and other Outpatient settings.

Regional Health Care Group will sell the FebriDx test throughout Australia and New Zealand with sales and marketing activities commencing immediately.

Lumos CEO, Doug Ward, said, "It is great to see the increased interest in our FebriDx test from one of the world's largest distributors of healthcare and medical products. Henry Schein has been a terrific and supportive partner for Lumos across Europe. With our recent US launch and the growing commercial interest in FebriDx, we are now preparing production of FebriDx to meet the anticipated growing demand for the product, to support our customers. It is very exciting to have Henry Schein as part of this strategy with their expanded distribution coverage for FebriDx in the Australian and New Zealand markets."